Sentences with phrase «effects of drug treatment»

However, it is a tricky subject to study as with observational data we often can not separate the effects of drug treatment from other risk factors such as maternal illnesses.

Not exact matches

The drug is particularly valuable to insurance companies, who will pay top dollar for treatments that help patients avoid the ravaging and expensive - to - treat effects of Hepatitis C.

In addition to partnering with Celgene (celg) to better track negative drug side effects, IBM (ibm) is applying its cognitive computing AI technology to recommend cancer treatment in rural areas in the U.S., India, and China, where there is a dearth of oncologists, said Deborah DiSanzo, general manager for IBM Watson Health.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Martin Shkreli, the founder and chief executive of Turing, said that the drug is so rarely used that the impact on the health system would be minuscule and that Turing would use the money it earns to develop better treatments for toxoplasmosis, with fewer side effects.

ALKS 3831 is a treatment for schizophrenia that avoids the side effects of weight gain and metabolic problems that the incumbent drug has, and a phase 3 trial for it should read out in the fall of 2018.

In contrast, positive expectations of treatment doubled the natural physiological or biochemical effect of the opioid drug among the healthy volunteers in the study.

Many would argue that it's possible for her to feel better without taking drugs: she could try the «talking cure» (regular sessions with a counselor), or an alternative treatment such as herbal or light therapy If she goes to an M.D., though, she'll likely carry my a prescription for an antidepressant such as Prozac or Zoloft — one of these brave new medicines that promise such good results with so few side effects,

Many laboratory tests were performed and chemotherapy — requiring intravenous punctures — was resumed, even though studies had shown that this type of cancer does not respond significantly, if at all, to drug treatment, and even though complications and side effects from the drugs were expected.

This was before Mackey had won a single Iditarod, let alone four straight; before he used what he calls his marathon style — catnapping as his sled moves and covering 100 - mile chunks at a moderate pace without prolonged rest, instead of sprinting from rest stop to rest stop like most other racers — to win an unprecedented double (the Yukon Quest, the world's other 1,000 - mile dogsled race, and just weeks later the Iditarod) not once but twice; before he became so dominant that slower competitors complained they had no chance to finish within five days of him (the requirement for an official place and a commemorative belt buckle); and before a rival pushed for drug testing at the 2010 Iditarod, suspecting that Mackey's secret was his prescription for medical marijuana to alleviate the side effects of cancer treatment.

Clomiphene Citrate: A prescription drug typically usedfor the treatment of female infertility, it is taken by male athletes to negatethe effects of increased estrogen, a result of anabolic steroid abuse.

HIV Medicine DOI: 10.1111/j.1468-1293.2011.00918.x IBFAN - Asia Position Statement on HIV and Infant Feeding, 13 October 2008 South African Tshwane Declaration on breastfeeding, S Afr J Clin Nutr 2011; 24 (4) UNAIDS 2010, Strategy Getting to Zero, UNAIDS Strategy 2011 — 2015 UNAIDS 2010, Agenda for Accelerated Country Action for Women, Girls, Gender Equality and HIV, 2010 - 2014 UNAIDS 2011, Countdown to Zero: Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive, 2011 - 2015 UNAIDS 2011 Press Release, 9 June, World leaders launch plan to eliminate new HIV infections among children by 2015 UNICEF Convention on the Rights of the Child UNICEF 2010, Facts for Life UNICEF 2011, Programming Guide, Infant and Young Child Feeding, 26 May 2011 WHO / UNICEF 2003, Global strategy for infant and young child feeding WHO 2007, Evidence on the long - term effects of breastfeeding: systematic reviews and meta - analysis WHO, UNAIDS, UNICEF 2009, Towards universal access: scaling up priority HIV / AIDS interventions in the health sector: progress report 2009 WHO 2009, Women and health, Today's evidence tomorrow's agenda WHO 2009, Acceptable medical reasons for use of breast - milk substitutes WHO 2009, Rapid advice: use of antiretroviral drugs for treating pregnant womenand preventing HIV Infection in infants WHO 2009, Rapid advice: revised WHO principles and recommendations on infant feeding in the context of HIV WHO 2010, Priority Interventions — HIV / AIDS prevention, treatment and care in the health sector WHO 2010, Guidelines on HIV and infant feeding: Principles and recomendations for infant feeding in the context of HIV and a summary of evidence WHO 2010, Annexure 7b to Guidelines on HIV and infant feeding.

Topics include the rights of persons with disabilities; the rights and responsibilities of drug users and ethical considerations for dignified addiction treatment; improving maternal and child health through advancements in women's rights; the effects of violence; access to affordable and appropriate health care and treatment; health disparities between different population groups; health during war and conflict; the health of internally displaced persons and refugees; and recognition of social and structural forces that impact the health of individuals and groups.

Administering the epilepsy drug retigabine opened the potassium channels and counteracted much of the toxin's effects, raising hopes of a treatment for these bites.

Abiraterone, approved in 2011 for the treatment of metastatic prostate cancer, has a «food effect» that is greater than any other marketed drug.

But while the drug had few side effects, it wasn't an effective treatment for either of the diseases.

While the once - daily dosing, low side - effects profile, and shortened treatment duration of interferon - free direct - acting antivirals are ideal for injection drug users, most trials of these therapies for HCV have excluded persons with recent injection drug use.

The long - term side effects of HIV drug treatment, such as increased cholesterol and heart disease, that crop up after 10 or 15 years will still occur.

Not all chemotherapy drugs are equally effective for all people, and finding the best treatment for an individual is a painful process of trial and error that wastes time and exposes patients to toxic side effects.

U.S. Health & Human Services Secretary Sylvia Burwell last year proposed a response, calling for a program to change doctors» opioid prescribing practices, to expand the use of naloxone, a drug used to reverse the effects of an opioid overdoses, and increase patient access to medication assisted treatments for opioid use disorders.

Therefore we believe that anti-VEGF treatment is a logical target for new drug treatments that could help enhance the effect of better lens design and placement, to prevent secondary cataract.»

«Our study suggests that in patients with heart failure and atrial fibrillation, catheter ablation is an effective alternative treatment that can help patients avoid or discontinue this drug to reduce the risk of these long - term side effects.»

«Our preclinical data suggest that combining low doses of these inhibitors will enhance the clinical effects of both drugs as a potential treatment for patients with AML,» says the senior author, Feyruz V. Rassool, PhD, associate professor of radiation oncology at the University of Maryland School of Medicine (UM SOM) and a researcher at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).

«This treatment is a new form of cell transplantation that utilizes the patient's own cells, so it does not require immunosuppressive drugs and, thus, avoids the side effects of those drugs,» says Scott Nyberg, M.D., Ph.D., a liver transplant surgeon at Mayo Clinic.

** DPP4 inhibitors are already used as a drug in the treatment of diabetes in order to prolong the effect of the two endogenous incretins GLP - 1 and GIP.

By targeting different hormones that help the body manage its own insulin levels — and by reducing side effects such as weight gain — three drugs recently approved by the FDA avoid most of the major problems associated with past diabetes treatments.

Researchers at New York Eye and Ear Infirmary of Mount Sinai showed that a microdose delivery system achieved a treatment effect comparable to a conventional eyedropper, while delivering less than four times the amount of drug.

While the individual effects of the drugs on virus - specific CTL differ somewhat depending on specific assays, schedules, and doses, treatment with any of the three HDAC inhibitors impaired the ability of CTL to kill HIV - infected immune cells.

«Most researchers have relied on cell lines to screen the effect of drugs and other treatments including viruses,» said Dr. Cripe, who also is a professor at The Ohio State University College of Medicine.

«Since epalrestat is already on the market and has no major adverse side effects, our study provides a proof of principle that it could become a valuable targeted drug for the clinical treatment of basal - like breast cancer,» Dong says.

«Once we understand how the brain systems producing the positive / euphoric and negative / anxiety effects of the drug interact, we might be able to produce treatments that address the balance between these two opposing actions, both of which serve as strong driving forces.

In phase I trials, researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.

But for transplant recipients, one prospect has remained unchanged: a lifetime of taking powerful drugs to suppress the immune system, a treatment that can have serious side effects.

If doctors can foretell schizophrenia, he says, then the benefits of preventive drug treatment outweigh the risks of side effects.

Further scientific investigation is warranted to determine how the drug achieves its effects as well as how they might be used in the treatment of «the ennui and anguish of impending death» as well as «alcoholism and other forms of drug addiction,» argues Charles Schuster, a neuroscientist at Wayne State University and a former director of the National Institute on Drug Abuse, in a commentary on the padrug achieves its effects as well as how they might be used in the treatment of «the ennui and anguish of impending death» as well as «alcoholism and other forms of drug addiction,» argues Charles Schuster, a neuroscientist at Wayne State University and a former director of the National Institute on Drug Abuse, in a commentary on the padrug addiction,» argues Charles Schuster, a neuroscientist at Wayne State University and a former director of the National Institute on Drug Abuse, in a commentary on the paDrug Abuse, in a commentary on the paper.

All 10 patients who received the CTL119 cells experienced mild cytokine release syndrome (CRS), a known potentially lethal type of toxicity, within a few days after receiving their infusions; however, none required treatment with tocilizumab, an immunosuppressant drug that blocks the effects of the inflammatory cytokine IL - 6.

Botox is best known as a cosmetic treatment for frown lines, but the drug also effectively treats the after effects of Bell's palsy and other serious facial nerve problems.

With support from pharma, we can refine these molecules over the next 10 - 20 years to develop anti-aging treatments which don't have the adverse effects of cancer drugs.»

Dr. Bachhuber and coauthors conclude: «To fully understand the effect of medical cannabis on the use of other drugs, prospective longitudinal studies randomizing patients to cannabis versus other treatments are urgently needed.»

Exploiting the same pre-clinical model used for their studies, the researchers are testing the efficacy of this kind of drug candidates against cancer stem cells, and the possibility of identifying combination regimens with standard chemotherapies with minimized toxic effects, with the perspective of their possible application for the treatment of human breast cancer.

The combination of the two drugs could potentially shorten treatment time, reduce the side effects of bedaquiline and improve patient outcomes for those suffering from TB.

The researchers will also study possible side effects from the modulation of gut bacteria and FXR by drug treatment.

«Not only does this shed light on how to potentially improve the effectiveness of triple negative cancer treatments, but it also sheds light on the full effect that these common drugs have on our bodies.»

«We are the first to publish these types of findings and, importantly it offers the opportunity to not only monitor the progress of the disease but also to determine if particular drugs / treatment are having an effect.»

In the lab, the antibiotics had no harmful effect on normal cells, and since they are already approved for use in humans, trials of new treatments should be simpler than with new drugs — saving time and money.

New findings by UH biomedical engineer Chandra Mohan and his team raise hope for a new class of drugs to treat lupus that may not include the long list of adverse risks and side effects often associated with current treatments.

New findings by a biomedical engineer and his team at the University of Houston (UH) raise hope for a new class of drugs to treat lupus that may not include the long list of adverse risks and side effects often associated with current treatments for this disease.

They studied the effects of this treatment in combination with ipilimumab, a U.S. Food and Drug Administration - approved immunotherapy.

Researchers in Sweden have just identified a number of drug targets that can be used in the development of new efficient treatment strategies with minimum side effects.

«The results of this study point to the potential for an alternative treatment that avoids the typical drug side effects, such as bloating and electrolyte imbalance, by imitating the body's natural physiology.»